Cargando…
Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology
Synthetic Biology has enabled new approaches to several medical applications including the development of immunotherapies based on bioengineered cells, and most notably the engineering of T-cells with tumor-targeting receptors, the Chimeric Antigen Receptor (CAR)-T cells. CAR-T-cells have successful...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431652/ https://www.ncbi.nlm.nih.gov/pubmed/30937303 http://dx.doi.org/10.3389/fbioe.2019.00043 |
_version_ | 1783405964050825216 |
---|---|
author | Caliendo, Fabio Dukhinova, Marina Siciliano, Velia |
author_facet | Caliendo, Fabio Dukhinova, Marina Siciliano, Velia |
author_sort | Caliendo, Fabio |
collection | PubMed |
description | Synthetic Biology has enabled new approaches to several medical applications including the development of immunotherapies based on bioengineered cells, and most notably the engineering of T-cells with tumor-targeting receptors, the Chimeric Antigen Receptor (CAR)-T cells. CAR-T-cells have successfully treated blood tumors such as large B-cell lymphoma and promise a new scenario of therapeutic interventions also for solid tumors. Learning the lesson from CAR-T cells, we can foster the reprogramming of T lymphocytes with enhanced survival and functional activity in depressing tumor microenvironment, or to challenge diseases such as infections, autoimmune and chronic inflammatory disorders. This review will focus on the most updated bioengineering approaches to increase control, and safety of T-cell activity and to immunomodulate the extracellular microenvironment to augment immune responses. We will also discuss on applications beyond cancer treatment with implications toward the understanding and cure of a broader range of diseases by means of mammalian cells engineering. |
format | Online Article Text |
id | pubmed-6431652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64316522019-04-01 Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology Caliendo, Fabio Dukhinova, Marina Siciliano, Velia Front Bioeng Biotechnol Bioengineering and Biotechnology Synthetic Biology has enabled new approaches to several medical applications including the development of immunotherapies based on bioengineered cells, and most notably the engineering of T-cells with tumor-targeting receptors, the Chimeric Antigen Receptor (CAR)-T cells. CAR-T-cells have successfully treated blood tumors such as large B-cell lymphoma and promise a new scenario of therapeutic interventions also for solid tumors. Learning the lesson from CAR-T cells, we can foster the reprogramming of T lymphocytes with enhanced survival and functional activity in depressing tumor microenvironment, or to challenge diseases such as infections, autoimmune and chronic inflammatory disorders. This review will focus on the most updated bioengineering approaches to increase control, and safety of T-cell activity and to immunomodulate the extracellular microenvironment to augment immune responses. We will also discuss on applications beyond cancer treatment with implications toward the understanding and cure of a broader range of diseases by means of mammalian cells engineering. Frontiers Media S.A. 2019-03-18 /pmc/articles/PMC6431652/ /pubmed/30937303 http://dx.doi.org/10.3389/fbioe.2019.00043 Text en Copyright © 2019 Caliendo, Dukhinova and Siciliano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Caliendo, Fabio Dukhinova, Marina Siciliano, Velia Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title | Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title_full | Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title_fullStr | Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title_full_unstemmed | Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title_short | Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology |
title_sort | engineered cell-based therapeutics: synthetic biology meets immunology |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431652/ https://www.ncbi.nlm.nih.gov/pubmed/30937303 http://dx.doi.org/10.3389/fbioe.2019.00043 |
work_keys_str_mv | AT caliendofabio engineeredcellbasedtherapeuticssyntheticbiologymeetsimmunology AT dukhinovamarina engineeredcellbasedtherapeuticssyntheticbiologymeetsimmunology AT sicilianovelia engineeredcellbasedtherapeuticssyntheticbiologymeetsimmunology |